Loading…
Investors allege violations in a legal action against the company.
Capricor Therapeutics, Inc. (Nasdaq: CAPR) is now facing a lawsuit filed by investors who claim the company violated securities laws. The lawsuit was initiated following allegations of undisclosed material information that impacted the company's stock performance.
No financial amounts or specific filings are associated with this legal action at this time. The lawsuit is in its early stages, with further details expected to emerge as the case progresses.
As of the latest available data, Capricor Therapeutics has a free float of 48,549,300 shares and 57,911,893 shares outstanding.
This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.